Predictive performance of gentamicin dosing nomograms

Drug Design, Development and Therapy

Volumn 8, Issue , 2014, Pages 1097-1106

  Lee, Jieon ^a   Yoon, Seonghae ^a   Shin, Donghoon ^a   Han, Hyekyung ^a   An, Hyungmi ^a,b   Lee, Jongtae ^a   Lim, Kyoung Soo ^c   Yu, Kyung Sang ^a   Lee, Howard ^a  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University   (South Korea)

^c CHA University   (South Korea)

Author keywords

Antibiotics; Bayesian method; Infectious endocarditis; Therapeutic drug monitoring

Indexed keywords

GENTAMICIN; ANTIINFECTIVE AGENT;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL ENDOCARDITIS; BARNES JEWISH HOSPITAL NOMOGRAM; BAYES THEOREM; CHEMILUMINESCENCE IMMUNOASSAY; CONTROLLED STUDY; DATA ANALYSIS SOFTWARE; DOSAGE SCHEDULE COMPARISON; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MONITORING; FEMALE; HARTFORD NOMOGRAM; HULL SARUBBI TABLE NORMOGRAM; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; MAXIMUM PLASMA CONCENTRATION; NORMOGRAM; PERFORMANCE MEASUREMENT SYSTEM; PHARMACOKINETICS; PLOTS AND CURVES; PREDICTIVE VALIDITY; RECOMMENDED DRUG DOSE; RULE OF EIGHTS NORMOGRAM; SANFORD GUIDE NORMOGRAM; SOUTH KOREA; STATISTICAL ANALYSIS; STATISTICAL MODEL; STATISTICAL PARAMETERS; STEADY STATE; THOMSON GUIDELINES NORMOGRAM; AGED; BACTERIAL INFECTIONS; COMPARATIVE STUDY; ENDOCARDITIS, BACTERIAL; MIDDLE AGED; NOMOGRAM; PRACTICE GUIDELINE; PROCEDURES; RETROSPECTIVE STUDY; UNIVERSITY HOSPITAL;

ADULT; AGED; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BAYES THEOREM; DRUG MONITORING; ENDOCARDITIS, BACTERIAL; FEMALE; GENTAMICINS; HOSPITALS, UNIVERSITY; HUMANS; MALE; MIDDLE AGED; NOMOGRAMS; PRACTICE GUIDELINES AS TOPIC; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES;

EID: 84906232318     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S66981     Document Type: Article

References (32)

1. Brunton LL, Chabner BA, Knollmann BC. Goodman and Gilman's Pharmacological Basis of Therapeutics. 12th ed. New York, NY: McGraw-Hill; 2011.
2. Charhon N, Neely MN, Bourguignon L, Maire P, Jelliffe RW, Goutelle S. Comparison of four renal function estimation equations for pharmacokinetic modeling of gentamicin in geriatric patients. Antimicrob Agents Chemother. 2012;56(4):1862-1869.
3. Hilmer SN, Tran K, Rubie P, et al. Gentamicin pharmacokinetics in old age and frailty. Br J Clin Pharmacol. 2011;71(2):224-231.
4. Bourguignon L, Goutelle S, De Saint-Martin JB, Maire P, Ducher M. Evaluation of various gentamicin dosage regimens in geriatric patients: a simulation study. Fundam Clin Pharmacol. 2010;24(1):109-113.
5. Lopez SA, Mulla H, Durward A, Tibby SM. Extended-interval gentamicin: population pharmacokinetics in pediatric critical illness. Pediatr Crit Care Med. 2010;11(2):267-274.
6. Abdel-Bari A, Mokhtar MS, Sabry NA, El-Shafi SA, Bazan NS. Once versus individualized multiple daily dosing of aminoglycosides in critically ill patients. Saudi Pharm J. 2011;19(1):9-17.
7. Ward K, Theiler RN. Once-daily dosing of gentamicin in obstetrics and gynecology. Clin Obstet Gynecol. 2008;51(3):498-506.
8. Tiwari S, Rehan HS, Chandra J, Mathur NN, Singh V. Efficacy and safety of a single daily dose of gentamicin in hospitalized Indian children: a quasi-randomized trial. J Antimicrob Chemother. 2009;64(5):1096-1101.
9. Philips BG, Somers VK. Drug Information Handbook for Cardiology. Washington, DC: Lexi-Comp, Inc.; 2000.
10. Béraud G, Le Moal G, Elsendoorn A, et al. A survey on the use of gentamicin in infective endocarditis. Eur J Clin Microbiol Infect Dis. 2012;31(7):1413-1418.
11. Al-Lanqawi Y, Capps P, Abdel-hamid M, et al. Therapeutic drug monitoring of gentamicin: evaluation of five nomograms for initial dosing at Al-Amiri Hospital in Kuwait. Med Princ Pract. 2007;16(5):348-354.
12. Wallace AW, Jones M, Bertino JS. Evaluation of four once-daily aminoglycoside dosing nomograms. Pharmacotherapy. 2002;22(9): 1077-1083.
13. Verma K. Base of a Research: Good Clinical Practice in Clinical Trials. J Clin Trials. 2013;3(1).
14. Lorian V. Antibiotics in Laboratory Medicine. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2005.
15. Thomson AH, Duncan N, Silverstein B, Alcock S, Jodrell D. Antimicrobial practice. Development of guidelines for gentamicin dosing. J Antimicrob Chemother. 1996;38(5):885-893.
16. Hull JH, Sarubbi FA Jr. Gentamicin serum concentrations: pharmacokinetic predictions. Ann Intern Med. 1976;85(2):183-189.
17. Lesar TS, Rotschafer JC, Strand LM, Solem LD, Zaske DE. Gentamicin dosing errors with four commonly used nomograms. JAMA. 1982;248(10):1190-1193.
18. Bailey TC, Little JR, Littenberg B, Reichley RM, Dunagan WC. A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis. 1997;24(5):786-795.
19. Gilbert DN, Moellering RC Jr, Eliopoulis GM, Saag MS. The Sanford Guide to Antimicrobial Therapy 2011. 41st ed. Sperryville, VA: Antimicrobial Therapy, Inc.; 2011.
20. Baddour LM, Wilson WR, Bayer AS, et al; Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease; Council on Cardiovascular Disease in the Young; Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia; American Heart Association; Infectious Diseases Society of America. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation. 2005;111(23):e394-e434.
21. Matzke GR, Jameson JJ, Halstenson CE. Gentamicin disposition in young and elderly patients with various degrees of renal function. J Clin Pharmacol. 1987;27(3):216-220.
22. Bourguignon L, Goutelle S, de Saint Martin JB, et al. [Interindividual pharmacokinetic variability in long-term antibiotherapy]. Med Mal Infect. 2010;40(1):38-41. French.
23. Janušonis T, Mačiulaitis R, Sveikata A, Milašius A, Kregždyte R. Rationality of administered gentamicin dose in cerebral coma patients treated in an intensive care unit. Medicina (Kaunas). 2011;47(2):79-84.
24. Rea RS, Capitano B, Bies R, Bigos KL, Smith R, Lee H. Suboptimal aminoglycoside dosing in critically ill patients. Ther Drug Monit. 2008;30(6):674-681.
25. Burton ME, Shaw LM, Schentag JJ, Evans WE, editors. Applied Pharmacokinetics and Pharmacodynamics: Principles of Therapeutic Drug Monitoring. 4th ed. Baltimore, MD: Lippincott Williams & Wilkins; 2006.
26. Jelliffe RW, Iglesias T, Hurst AK, Foo KA, Rodriguez J. Individualising gentamicin dosage regimens. A comparative review of selected models, data fitting methods and monitoring strategies. Clin Pharmacokinet. 1991;21(6):461-478.
27. Xuan D, Nicolau DP, Nightingale CH. Population pharmacokinetics of gentamicin in hospitalized patients receiving once-daily dosing. Int J Antimicrob Agents. 2004;23(3):291-295.
28. Sawchuk RJ, Zaske DE. Pharmacokinetics of dosing regimens which utilize multiple intravenous infusions: gentamicin in burn patients. J Pharmacokinet Biopharm. 1976;4(2):183-195.
29. McNamara DR, Nafziger AN, Menhinick AM, Bertino JS. A dose-ranging study of gentamicin pharmacokinetics: implications for extended interval aminoglycoside therapy. J Clin Pharmacol. 2001; 41(4):374-377.
30. Anaizi N. Once-daily dosing of aminoglycosides. A consensus document. Int J Clin Pharmacol Ther. 1997;35(6):223-226.
31. Buchholtz K, Larsen CT, Schaadt B, Hassager C, Bruun NE. Once versus twice daily gentamicin dosing for infective endocarditis: a randomized clinical trial. Cardiology. 2011;119(2):65-71.
32. Habib G, Hoen B, Tornos P, et al; ESC Committee for Practice Guidelines. Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009): the Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and the International Society of Chemotherapy (ISC) for Infection and Cancer. Eur Heart J. 2009;30(19):2369-2413.